Conjugated To Proteinaceous Toxin Or Fragment Thereof (e.g., Conjugated To Diphtheria Toxin, Pseudomonas Exotoxin, Ricin, Gelonin, Abrin, Etc.) Patents (Class 424/183.1)
  • Patent number: 10730942
    Abstract: The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: August 4, 2020
    Assignee: UCL Business Ltd
    Inventors: Martin Pule, Paul Maciocia, Ben Grimshaw
  • Patent number: 10617691
    Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: April 14, 2020
    Assignee: MORPHOSYS AG
    Inventors: Jan Endell, Rainer Boxhammer, Mark Winderlich
  • Patent number: 10611844
    Abstract: The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to the epidermal growth factor receptor (EGFR) as a clinical target for treatment of neurological disorders, preferably in conjunction with neuropathic pain. The invention relates in more detail to compositions comprising inhibitors of EGFR.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: April 7, 2020
    Assignee: Sykehuset Sørlandet HF
    Inventors: Christian Kersten, Marte Grønlie Cameron, Svein Mjåland
  • Patent number: 10227407
    Abstract: Object of the present invention is to provide various anti-podoplanin antibodies useful as a drug or reagent. The present invention provides an anti-podoplanin antibody or antigen-binding fragment thereof, each having an epitope in any of the following regions in the amino acid sequence of podoplanin represented by SEQ ID NO: 1: (i) from position 56 to position 80, (ii) from position 81 to position 103, (iii) from position 81 to position 88, and (iv) from position 25 to position 57.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 12, 2019
    Assignees: ZENOAQ RESOURCE CO., LTD.
    Inventors: Yukinari Kato, Mika Kato
  • Patent number: 10081672
    Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: September 25, 2018
    Assignee: National Research Council of Canada
    Inventors: Wei-Gang Hu, Laurel M. Negrych, Damon Chau, Junfei Yin, Scott J. Jager, John W. Cherwonogrodzky
  • Patent number: 9982018
    Abstract: The invention relates to tumor therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer and other disorders and diseases. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 29, 2018
    Assignee: Heidelberg Pharma GmbH
    Inventors: Christoph Müller, Jan Anderl, Werner Simon, Christian Lutz, Torsten Hechler
  • Patent number: 9580512
    Abstract: The invention relates to the use of a binding member that binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody that binds to SCR1 and SCR2 of CD55 and neutralizing CD55 and making cancer cells susceptible to complement-mediated attack.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: February 28, 2017
    Assignee: Cancer Research Technology Limited
    Inventor: Lindy Gillian Durrant
  • Patent number: 9399681
    Abstract: The invention relates to tumor therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by a linker comprising a urea moiety, which are useful in the treatment of cancer. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: July 26, 2016
    Assignee: Heldelberg Pharma GmbH
    Inventors: Jan Anderl, Werner Simon, Christoph Mueller
  • Patent number: 9381205
    Abstract: The present invention provides for anti-EFNA4 antibody-drug conjugates and methods for preparing and using the same.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: July 5, 2016
    Assignees: Pfizer, Inc., Stemcentrx, Inc.
    Inventors: Marc Isaac Damelin, Kiran Manohar Khandke, Puja Sapra, Alexander John Bankovich, Scott J. Dylla
  • Patent number: 9364557
    Abstract: Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: June 14, 2016
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SCOTT AND WHITE HEALTHCARE
    Inventors: David M. Neville, Jr., Jung-Hee Woo, Arthur Frankel
  • Patent number: 9309305
    Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: April 12, 2016
    Assignee: National Research Council of Canada
    Inventors: Wei-Gang Hu, Laurel M Negrych, Damon Chau, Junfei Yin, Scott J. Jager, John W. Cherwonogrodzky
  • Patent number: 9173732
    Abstract: Provided herein are new methods for the treatment of hyperproliferative diseases affecting the spinal cord, including the use of biodegradable polymers to treat spinal cord tumor recessing, i.e., to patch open zones left by spinal tumor removal. Biocompatible polymeric materials are tailored to fill areas previously occupied by tumors, e.g., materials in the form of tubular articles configured for insertion into the spinal column after surgical removal of a tumor. These protective articles may also include medicinal agents that stimulate spinal column neural regeneration, such as medicines or donor neuronal cells such as human neural stem cells, thus assisting patients to recover motorsensory function after spinal tumor surgery.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: November 3, 2015
    Assignees: The Children's Medical Center Corporation, Massachusetts Institute of Technology
    Inventors: Robert S. Langer, Rajiv Saigal, Yang Teng, Eric Woodard
  • Patent number: 9107904
    Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 18, 2015
    Assignee: Massachusetts Institute of Technology
    Inventors: Darrell Irvine, Haipeng Liu
  • Publication number: 20150147330
    Abstract: Described herein is the identification of a panel of high affinity monoclonal antibodies that bind GPC3. The disclosed antibodies recognize native GPC3 on the surface of cancer cells, as well as soluble GPC3. The highest affinity antibody (YP7) was further characterized and shown to be highly sensitive in that it was capable of detecting cancer cells with low expression of GPC3. YP7 also exhibited significant HCC tumor growth inhibition in vivo. Immunotoxins comprising the antibodies disclosed herein fused to PE38 exhibited very high binding affinity for GPC3-expressing cells and significantly inhibited GPC3-expressing cancer cell growth. Thus, the high-affinity monoclonal antibodies disclosed herein can be used for the diagnosis and treatment of GPC3-expressing cancers.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 28, 2015
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Mitchell Ho, Yen T. Phung, Wei Gao, Yifan Zhang
  • Patent number: 9040058
    Abstract: The present invention relates to a fermentation medium for cultivating Corynebacterium diphtheriae. The present invention also relates to the use of the fermentation medium in processes for obtaining diphtheria toxin from the Corynebacterium diphtheriae bacteria being cultivated and the preparation of vaccines using the diphtheria toxin obtained in the processes. The present invention further relates to a purification and detoxification processes specifically adapted for preparing a diphtheria toxoid for inclusion into a vaccine.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 26, 2015
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Friedrich Blackkolb, Bernd Becker, Martha Reith, Manfred Isenberg, Anne Katrin Hilbert
  • Publication number: 20150140023
    Abstract: The monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, the antibody or the fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. Also artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.
    Type: Application
    Filed: December 23, 2014
    Publication date: May 21, 2015
    Inventors: Stephane BIRKLE, Jean-Marie MUSSINI, Jacques AUBRY, Jacques BARBET, Jean-Francois CHATAL, Beatrice CLEMENCEAU
  • Patent number: 9029509
    Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 12, 2015
    Assignee: The Regents of the University of California
    Inventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
  • Publication number: 20150125445
    Abstract: The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 7, 2015
    Inventors: John C. Herr, Eusebio S. Pires, Austin Herr
  • Patent number: 9023356
    Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: May 5, 2015
    Assignees: Ludwig Institute for Cancer Research Ltd, The Regents of the University of California
    Inventors: Terrance Grant Johns, Webster Cavenee, Frank Furnari, Andrew Scott
  • Publication number: 20150118256
    Abstract: The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
    Type: Application
    Filed: March 25, 2014
    Publication date: April 30, 2015
    Applicant: Pfizer Vaccines LLC
    Inventors: Brian Robert Champion, David Robert Stead, Paul Andrew Wright
  • Publication number: 20150110785
    Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
  • Publication number: 20150104382
    Abstract: Screening and diagnostic reagents, kits and methods for primary and or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach for esophageal cancer are disclosed.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 16, 2015
    Inventors: Scott A. Waldman, Jason Park, Stephanie Schulz
  • Publication number: 20150098943
    Abstract: The invention relates to a protein construct, comprising (i) a targeting moiety that is capable of binding to a target cell, and (ii) an effector immunogenic moiety that is capable of triggering an existing, vaccine-induced or natural, immune response. The protein construct, that is preferably in the form of a heteromultimeric protein, is useful for redirecting an immune response that was pre-existing in a patient, toward an undesired target cell.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 9, 2015
    Inventors: Jacques Henri Max Cohen, Wael Mahmoud, Marcelle Tonye Libyh, Nathalie Godin, Annelise Gimenez, Thierry Tabary, Beatrice Donvito, Daniel Baty, Xavier Dervillez
  • Patent number: 8999334
    Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: April 7, 2015
    Assignee: Viventia Bio Inc.
    Inventors: Francina C. Chahal, Jeannick Cizeau
  • Patent number: 8999344
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: April 7, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Publication number: 20150086574
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Application
    Filed: August 12, 2014
    Publication date: March 26, 2015
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • Publication number: 20150086478
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: May 2, 2013
    Publication date: March 26, 2015
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejr Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
  • Publication number: 20150079089
    Abstract: Disclosed herein are methods and compositions for modulating neovascularization. The disclosed compositions find particular use in the treatment of uterine cancers, specifically endometrial cancers.
    Type: Application
    Filed: February 6, 2013
    Publication date: March 19, 2015
    Inventors: Madhuri Wadehra, Jonathan Braun, Lynn K. Gordon
  • Publication number: 20150079116
    Abstract: NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 19, 2015
    Inventors: Jonathan Braun, Lin Lin
  • Publication number: 20150072895
    Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Inventors: David B. KRIZMAN, Wei-Li LIAO, Sheeno THYPARAMBIL, Todd HEMBROUGH
  • Publication number: 20150071852
    Abstract: In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.
    Type: Application
    Filed: April 10, 2014
    Publication date: March 12, 2015
    Applicant: John Wayne Cancer Institute
    Inventor: Xiaojiang Cui
  • Patent number: 8968742
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Patent number: 8968741
    Abstract: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: March 3, 2015
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Alane M. Gray, Wei-Ching Liang, Yan Wu, Shang-Fan Yu
  • Publication number: 20150056135
    Abstract: Methods of treating cancer in a patient are provided. In some embodiments the method comprises administering an antibody that is capable of binding to the extracellular domain of PSMA after first administering a hormonal therapy.
    Type: Application
    Filed: November 10, 2014
    Publication date: February 26, 2015
    Inventor: Neil H. Bander
  • Publication number: 20150044212
    Abstract: The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.
    Type: Application
    Filed: August 7, 2014
    Publication date: February 12, 2015
    Inventors: Feng Xiao, Xiao-Chi Jia, Meina Liang, Orit Foord, Scott Klakamp, Kam Fai Tse, Vincent A. Pollack, Luca Rastelli, John Herrmann, Henri Lichenstein, Michael E. Jeffers, William J. LaRochelle, Gulshan Ara, Peter Mezes, Andrei Chapoval, Cyrus Karkaria, Michael Torgov, Juan Davagnino
  • Publication number: 20150037251
    Abstract: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.
    Type: Application
    Filed: February 18, 2013
    Publication date: February 5, 2015
    Applicants: UNIVERSITAT BERN, CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS
    Inventors: Christa Rhiner, Evgeniya Pertova, Jesus M. Lopez-Gay, Eduardo Moreno
  • Publication number: 20150037340
    Abstract: The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Application
    Filed: November 5, 2012
    Publication date: February 5, 2015
    Inventors: Charlotte Beau-Larvor, Liliane Goetsch, Nicolas Boute
  • Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Publication number: 20150030586
    Abstract: Compositions and methods for the therapy and diagnosis of cancer are disclosed. For example, illustrative compositions comprise one or more cancer-associated antibodies, polypeptides, polynucleotides, antigen presenting cells, and the like. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly cancer.
    Type: Application
    Filed: June 19, 2012
    Publication date: January 29, 2015
    Inventors: Sarah Ellen Warren, Carl Weissman
  • Publication number: 20150023870
    Abstract: Disclosed herein are compositions and methods of use comprising hexavalent DNL complexes. Preferably, the complexes comprise anti-CD20 and/or anti-CD22 antibodies or fragments thereof. More preferably, the anti-CD20 antibody is veltuzumab and the anti-CD22 antibody is epratuzumab. Administration of the subject hexavalent DNL complexes induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. In most preferred embodiments, the DNL complexes increase levels of phosphorylated p38 and PTEN, decrease levels of phosphorylated Lyn, Akt, ERK, IKK?/? and I?B?, increase expression of RKIP and Bax and decrease expression of Mcl-1, Bcl-xL, Bcl-2, and phospho-BAD in target cells. The subject DNL complexes show EC50 values for inhibiting tumor cell growth in the low nanomolar or even sub-nanomolar concentration range.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 22, 2015
    Applicant: IBC PHARMACEUTICALS, INC.
    Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
  • Publication number: 20150023871
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 22, 2015
    Applicant: GENENTECH, INC.
    Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
  • Publication number: 20150023965
    Abstract: Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed.
    Type: Application
    Filed: July 16, 2014
    Publication date: January 22, 2015
    Applicant: FOUNDATION MEDICINE, INC.
    Inventors: Siraj Mahamed Ali, Matthew J. Hawryluk, Jeffrey S. Ross, Philip James Stephens
  • Patent number: 8916162
    Abstract: Methods and compositions pertaining to botulinum neurotoxin (BoNT) light chain epitopes are provided. In particular, the methods and compositions relate to the use of real and mimetic BoNT light chain epitopes for generating an immune response in a subject, and for immunization against BoNT toxicity. Methods and compositions for detecting, isolating, and purifying BoNT epitopes and anti-BoNT antibodies are also provided.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: December 23, 2014
    Inventor: Alexey Gennadievich Zdanovsky
  • Patent number: 8916161
    Abstract: The present invention provides a method of treating BPH using modified pore-forming proteins (MPPs). These MPPs are derived from naturally occurring cytotoxic proteins (nPPs) that kill cells by forming pores or channels in the cell membrane, resulting in cell death. The MPPs are generated by modification of the nPPs such that they are capable of being selectively activated at normal prostate cells. Such modification may include the addition of a prostate-specific protease cleavage site to the activation sequence, and/or the addition of a prostate-specific targeting domain to allow selective targeting of prostate cells. These MPPs are capable of selectively targeting and killing normal prostate cells in vivo. The MPPs may be used either alone or in combination with other therapies for the treatment of BPH.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: December 23, 2014
    Assignee: Sophiris Bio Inc.
    Inventor: James Thomas Buckley
  • Publication number: 20140369924
    Abstract: Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.
    Type: Application
    Filed: May 12, 2014
    Publication date: December 18, 2014
    Inventors: Irving L. Weissman, Ravindra Majeti, Arash Ash Alizadeh, Mark P. Chao
  • Publication number: 20140369926
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 18, 2014
    Inventors: J. Andrew BRISTOL, Judith A. KANTOR
  • Publication number: 20140348743
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: April 9, 2014
    Publication date: November 27, 2014
    Applicants: Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
  • Patent number: 8894973
    Abstract: The invention is a method for the differential diagnosis of chronic schizophrenia or chronic alcoholism, by imaging the brain of a subject to detect any or all of the markers phosphocreatine (PCr), N-acetyl aspartate divided by the total creatine signal (NA/Crt), and synaptic phosphodiester (sPDE), and determining any increase or decrease in the presence of such markers compared to normal levels in specified anatomic areas of the brain. The output of such a method, resulting from such imaging, is presented to be viewed by a diagnostician in order to support the differential diagnosis based on the data output.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: November 25, 2014
    Inventors: Jay W. Pettegrew, Kanagasabai Panchalingam
  • Patent number: 8895014
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: November 25, 2014
    Assignee: Glycovaxyn AG
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
  • Publication number: 20140341802
    Abstract: Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.
    Type: Application
    Filed: May 12, 2014
    Publication date: November 20, 2014
    Applicant: Woomera Therapeutics
    Inventors: William G. North, Roy H.L. Pang